Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (536)	1/25/2002 1:14:03 PM
From: JMarcus	Respond to of 548

<<Dear Alliance NetFriend: We are pleased to be receiving national media attention regarding Oxygent, the oxygen carrier that Alliance is developing to avoid the need for donor blood. Oxygent was featured on a segment entitled "New blood substitute shows promise" that is being aired on NBC news stations and is featured on the wnbc.com website at wnbc.com The NBC news story highlights the need for an alternative to blood due to blood shortages that are being experienced across the country. As we announced last week, we have taken important steps in moving forward with the clinical development of Oxygent by submitting an Interim Integrated Safety Summary and a new Phase 3 clinical plan to the US FDA and to European regulatory authorities. We will keep you informed as we progress with our new clinical plan. Sincerely, Gwen Gwen Rosenberg Vice President, Corporate Communications Alliance Pharmaceutical Corp.>>